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Background: Acute respiratory distress syndrome (ARDS) is a life-threatening critical illness, characterised by qualitative
and quantitative surfactant compositional changes associated with premature airway collapse, gas-exchange
abnormalities and acute hypoxic respiratory failure. The underlying mechanisms for this dysregulation in surfactant
metabolisms are not fully explored. Lack of therapeutic benefits from clinical trials, highlight the importance of detailed
in-vivo analysis and characterisation of ARDS patients according to patterns of surfactant synthesis and metabolism.
Methods: Ten patients with moderate to severe ARDS were recruited. Most (90%) suffered from pneumonia. They
had an infusion of methyl-D9-choline chloride and small volume bronchoalveolar lavage fluid (BALF) was obtained at
0,6,12,24,48,72 and 96 hours. Controls were healthy volunteers, who had BALF at 24 and 48 hours after methyl-D9-choline
infusion. Compositional analysis and enrichment patterns of stable isotope labelling of surfactant phosphatidylcholine
(PC) was determined by electrospray ionisation mass spectrometry.
Results: BALF of patients with ARDS consisted of diminished total PC and fractional PC16:0/16:0 concentrations
compared to healthy controls. Compositional analysis revealed, reductions in fractional compositions of saturated
PC species with elevated levels of longer acyl chain unsaturated PC species. Molecular specificity of newly synthesised
PC fraction showed time course variation, with lower PC16:0/16:0 composition at earlier time points, but achieved
near equilibrium with endogenous composition at 48 hours after methyl-D9-choline infusion. The enrichment of
methyl-D9-choline into surfactant total PC is nearly doubled in patients, with considerable variation between individuals.
Conclusions: This study demonstrate significant alterations in composition and kinetics of surfactant PC extracted from
ARDS patients. This novel approach may facilitate biochemical phenotyping of ARDS patients according to surfactant
synthesis and metabolism, enabling individualised treatment approaches for the management of ARDS patients
in the future.
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Surfactant complex is a mixture of phospholipids and
proteins. Phosphatidylcholine is the major surfactant
phospholipid and among the several species, PC16:0/
16:0 is the principle PC, thought to be actively involved
in surface reduction at the air-liquid interface [1]. In
patients with respiratory failure secondary to acute
respiratory distress syndrome (ARDS), the lavaged sur-
factant complex show compositional derangement and
lacks adequate surface activity [2,3]. Consequently, these
changes are likely to contribute to the detrimental clinical
features of severe hypoxemia, poor lung compliance
and lung atelectasis, which are characteristic of ARDS.
However, the exact underlying mechanisms for this
dysregulation in surfactant metabolism is not known.
The plausible hypothesises are complex and includes
decreased synthesis/ secretion, increased breakdown by
hydrolysis or oxidation, increased clearance and or func-
tional inhibition by invasion of non-surfactant material
into the alveolus [4]. Human in-vivo studies exploring
these mechanisms are lacking and consequently, there
remains a significant gap in the understanding of sur-
factant metabolism during acute alveolar injury.
ARDS is a heterogeneous disease process with signifi-
cant variations in aetiology, pathophysiology, response to
therapy and outcome. Furthermore, it imposes significant
morbidity and mortality and lack of defined pharmacother-
apies to moderate disease process remains an enduring
challenge. Current diagnostic definitions fail to identify
a homogenous population, and are limited by the lack of
specificity and information regarding possible underlying
genophenotypes. The disappointing results from surfactant
replacement clinical trials in adults, reiterate the necessity
for in-vivo human studies to explore the exact underlying
mechanisms leading to the disordered surfactant metabol-
ism evident in ARDS. Such studies may enable an indivi-
dualised treatment strategy in the future after biochemical
phenotyping of patients according to their intrinsic surfac-
tant metabolism.
Traditional assessments of pulmonary surfactant con-
sisted of isolation with sequential bronchoalveolar lavage
fluid (BALF) and subsequent separation of surfactant
phospholipids by liquid chromatography [3,5]. Such studies
provided significant insights into surfactant compositional
abnormalities in patients with ARDS. However, quantitative
phospholipid assessments were unpredictable due to vari-
ability in surfactant recovery by BALF. Furthermore, such
approaches lack specific information regarding the dynam-
ics of surfactant synthesis and turnover. Stable isotope
labelling coupled with analytical methods of electrospray
ionization mass spectrometry (ESI-MS/MS), provides a
novel approach to the dynamic assessment of surfactant
metabolism in addition to highly specific molecular analysis
of surfactant phospholipids [6]. Consequently, we used thismethodology to characterise surfactant phosphatidylcholine
kinetics in patients with ARDS.
Methods
Study population
Following approval from National Research Ethics
Committee (10/WNo01/52) and University Hospital
Southampton Research and Development Department
(CRI0244), patients with ARDS were identified and
recruited from general intensive care unit at University
Hospital Southampton NHS Foundation Trust. The diag-
nosis of ARDS was based on the American European
Consensus Conference diagnostic criteria [7]. All eligible
patients were enrolled after informed assent was obtained
from patient’s next of kin within 72 hours of onset of
ARDS. All patients were sedated and required invasive
mechanical ventilation. The control group consisted of
nine healthy volunteers without any prior history of lung
diseases and were all non-smokers.
Methyl-D9 choline chloride
Deuterated methyl-D9 choline chloride is a stable isotope
of choline, which can be used to probe dynamic PC syn-
thetic pathways in-vivo and has been successfully applied
to quantify surfactant PC flux via the CDP-choline path-
way in healthy human volunteers and in animal models
[8,9]. Following informed assent or consent, patients
and controls had an intravenous infusion of methyl-D9
choline chloride (3.6 mg/kg) for a three hour period.
Sample collection and processing
Bronchoalveolar lavage fluid (BALF) was obtained via a
fibre-optic bronchoscope (Olympus BF P60). All patients
were intubated with an endotracheal tube (size 7–9)
and mechanically ventilated. Prior to the bronchoscopy,
patients were pre-oxygenated with 100% oxygen and
this was continued throughout the procedure. Patients
were given additional sedation if required to facilitate
the procedure. Bronchoscopy was not performed on
patients with inspired oxygen (Fi02) of >80% and was
abandoned, when there was a significant desaturation
defined as pulse oximetry oxygen saturation of <85%.
Small volumes of BALF were collected by suctioning
after instillation of 10-20 mls of warm sterile saline
from a single lobar bronchus (either from middle or lower
lobes). This was then rotated (in the order of right middle
lobe, left middle lobe, right lower lobe and left lower
lobe) for the subsequent lavages to minimise theoretical
concerns, that repeated lavage of the same lobe could
be detrimental to surfactant concentration or function
in that lobe. This small volume BALF was performed at
baseline before the administration of methyl-D9-choline
chloride infusion, and at 6, 12, 24, 48, 72, 96 hours after
the infusion. The reason for the frequent sampling





Pa02/Fi02 ratio (mmHg) 113.4 (63.5–169.3)
Lung Injury Score 3.2 (2.5–3.5)
APACHE II Score 23.2 (17–30)
Tidal volumes (ml/kg IBW) 6.7 ± 1.3
PEEP (cm of H20) 10.8 ± 3.1
Ventilation days 8.9 (3–19)
Length of ICU stay 12.4 (3–35)
Length of hospital stay 18.6 (9–53)
ICU survival 50%
M, male; F, female; Pa02/Fi02 ratio, ratio of partial pressure of arterial oxygen
and fraction of inspired oxygen; APACHE, acute physiology and chronic health
evaluation; IBW, ideal body weight; ICU, intensive care unit. Data expressed as
mean ± standard deviation or mean (range).
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lysis is performed at this stage, which could be utilised to
target therapeutic interventions. For healthy volunteers,
small volume BALF was obtained at 24 and 48 hours after
methyl-D9-choline infusion.
BALF was transferred at 4°C to the processing labora-
tory. 10ul of Butylated Hydroxy Toluene (BHT) (20 g/L)
solution was added to all samples as an anti-oxidant.
Then the samples were filtered through a 100um nylon
cell strainer and centrifuged at 100 x g for 20 seconds at
4°C. The resultant liquid material was further centrifuged
at 400 g for 10 minutes at 4°C. The supernatant was
aliquoted in eppendorfs and stored in a −80°C freezer.
Phospholipid extraction
Total lipid extraction was performed using the Bligh and
Dyer method [10]. Samples were made up to a volume
of 800ul with 0.9% NaCl and dimyristol-PC (PC14:0/
14:0) was added as internal standard (IS). One ml of
chloroform and 2 mls of methanol were added to the
samples, followed by further 1 ml of chloroform and
1 ml of distilled water. Sharper resolution was achieved
by centrifuging at 400 g at 20°C for 20 minutes. The
lower lipid rich layer was then removed and dried under
a nitrogen concentrator at 40°C. Once dried further 1 ml
of chloroform was added and dried again to be analysed
by mass spectrometry.
Mass spectrometry analysis and data extraction
The dried phospholipid fraction was suspended in a
mixture of methanol-butanol-water-concentrated NH4OH
(6:2:1.6:0.4 v/v), and was injected by syringe pump at a
rate of 8ul/ml into the electrospray ionisation interface of
a Xevo TQ mass spectrometer (Waters Corporation, UK)
(ESI-MS/MS). The endogenous and newly produced PC
species were calculated from MS/MS fragmentations of
precursor ion m/z +184 and m/z + 193 respectively [8,9].
Dedicated excel spread sheets were used to quantify ion
peaks after corrections for 13C-isotopic effects.
Statistical analysis
Data were summarised by means, standard deviation (SD)
and standard errors of means (SEM). The difference in
composition in each group was examined by calculating
the difference in means. Single comparisons were analysed




Ten patients with ARDS, including 5 males and 5 females
with a mean age of 61 and a range of 38–90 were recruited.
The mean Pa02/Fi02 ratio was 113 mmHg, suggesting mod-
erate to severe hypoxic respiratory failure. The APACHE IIscore, which defines the overall severity of their illness, was
23.2. All patients were intubated for respiratory failure and
were managed with invasive ventilation. The duration of
mechanical ventilation was 8.9 days. The mean length of
ICU and hospital stay was 12.4 and 18.6 days respectively.
The ICU mortality was 50%.
The majority of patients presented with pneumonia
(90%) and most (80%) needed at least one other organ
support in addition to invasive mechanical ventilation.
One patient did not survive beyond 24 hours from enrol-
ment and hence, only had BALF samples up to 12 hours
after methyl-D9-choline infusion. While all other patients
had small volume BALF at least until 48 hours, some did
not have theirs at later time points (72 and 96 hours) due
to either planned extubation or death. All patients were
enrolled within 72 hours of diagnosis of ARDS and the
actual mean enrolment time was <48 hours. The summary
of patient’s characteristics is listed in Table 1.
Small volume BALF was tolerated by all without any
significant immediate complications including pneumo-
thoraxes or cardiac arrhythmias. Patients needed add-
itional sedation with boluses of propofol (40 ± 3 mgs) or
midazolam (2 ± 0.3 mgs) for this procedure. There were
no significant step-up in oxygen requirement post proced-
ure (Fi02-pre 54 ± 10%, Fi02-post 55 ± 9%). The oxygen
saturation pre- procedure was 94 ± 2% and post procedure
was 91 ± 3%.
Mass spectrometry analysis of BALF PC
The molecular species of glycerophospholipids such as
phosphatidylcholines can be classified according to the
nature of esterified bond at the sn-1 (carbon-1) and sn-2
(carbon-2) positions of glycerol back bone, the number
of carbon atoms in the fatty acid chains and the number
Figure 1 Bronchoalveolar lavage phosphatidylcholine mass spectra from a healthy control for precursor scans of P184 (A) (endogenous
phosphatidylcholine composition) and precursor scans of P193 (B) (newly synthesised deuterated phosphatidylcholine composition at
24 hours after methyl-D9 choline infusion). The relative signal intensity of spectra B is nearly one hundredth of spectra A. The m/z 678 represents
an internal standard of PC14:0/14:0. The methyl-D9-labelled phosphatidylcholine composition consisted of phosphatidylcholine species with 9 mass
units higher than that of endogenous composition. PC, phosphatidylcholine; m/z, mass to charge ratio.
Figure 2 Bronchoalveolar lavage total phosphatidylcholine
concentrations over time for patients and controls. Measured
by sum of all phosphatidylcholine species present >1% abundance.
[Controls (n) =9 for both time points, patients (n) =10, n = 9, n = 10,
n = 9, n = 9, n = 8, n = 7 for time points 0,6,12,24,48,72 and 96
respectively]. Data expressed as mean ± SEM. BALF, bronchoalveolar
lavage fluid; PC, phosphatidylcholine.
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fatty acid chain determines the length of the chain and
the number of double bonds in the side chain denotes
their degree of saturation/unsaturation. For instance,
dipalmitoyl PC is denoted as PC16:0/16:0, where there
are two saturated fatty acids chains with sixteen carbons
length. The BALF endogenous PC molecular composition
was analysed by ESI-MS/MS from precursor scans of m/z
184 (P184). Subsequent enrichment of methyl-D9 choline,
resulted in the generation of PC species with 9 mass units
higher than those of endogenous composition. These were
readily identified by precursor scans of m/z 193 (P193). A
typical mass spectra for BALF PC endogenous and newly
generated PC composition from controls is shown by
Figure 1, with PC species for that particular mass charge
ratio. In general, the most abundant PC species were
PC16:0/16:0, PC16:0/18:1, PC16:0/14:0 and PC16:0/16:1.
This distinctive PC composition mainly consisting of
saturated PC species is a typical feature of pulmonary
surfactant [1].
Total Surfactant PC and PC16:0/16:0 concentration
Total surfactant PC concentration was estimated by the
sum of all PC species present at greater than 1% abundance
corrected for recovery of PC14:0/14:0 internal standard.
There was a significant reduction (P < 0.0001) in the total
BALF PC isolated in patients compared to healthy controls
Figure 3 Comparison of bronchoalveolar lavage surfactant
phosphatidylcholine composition between patients at enrolment
(T = 0 Hrs) and controls at earliest time point after enrolment
(T = 24 Hrs). Controls (n) =9 and patients (n) =10. Presented as
mean ± SEM, †, P < 0.0001; ‡, P < 0.05. PC, phosphatidylcholine.
Figure 4 Individual variations of surfactant specific phosphatidylcholi
controls at earliest time point after enrolment (T=24 Hrs) (A), and pat
PC, phosphatidylcholine; C, individual controls; P, individual patients.
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Hrs), the mean total PC concentration in the patient group
was 13 ± 4 nmol/ml and accounted for only 30% of the
controls. A further reduction in PC concentration was
noted at 12 hours after enrolment. Additionally in patients,
there was no significant recovery in total PC concentration
over the investigative period up to 96 hours (Figure 2).
PC16:0/16:0 concentrations were also much lower in pa-
tients at enrolment (2.6 ± 0.3 nmol/ml) and only accounted
for about 10% of the healthy control values.
Surfactant PC molecular composition at enrolment
At enrolment (T = 0 Hrs), surfactant PC composition of
patients consisted of PC16:0/16:0 (27.4 ± 2.8%), PC16:0/
18:1 (23.2 ± 1.2%), PC16:0/18:2 (10.6 ± 1.6%) and PC18:0/
18:2 (9.7 ± 1.0%) with other PC species in much lesser
abundance. Compared to the healthy controls, surfactant
recovered from ARDS patients had significantly lower
proportions of surfactant specific PC species, PC16:0/16:0
[mean difference (MD) of 29%, P < 0.0001] and PC16:0/
14:0 (MD of 4% P = 0.02). The relative contribution of
PC16:0/16:1 did not change between groups, while the
longer acyl chain unsaturated PC species were elevated
in patients [PC16:0/18:1 (MD 11%, P < 0.0001), PC16:0/ne species (PC16:0/14:0), PC16:0/16:1 and PC16:0/16:0) between
ients at enrolment (T=0) (B). Controls (n) =09 and patients (n) =10.
Dushianthan et al. Respiratory Research 2014, 15:128 Page 6 of 11
http://respiratory-research.com/content/15/1/12818:2 (MD 5.2%, P = 0.0014) and PC18:0/18:2 (MD of
7.5% P < 0.0001, Figure 3). The saturated PC species
characteristic of surfactant (PC16:0/16:0 and PC16:0/
14:0) gradually increased for patients over time, with
decreased relative concentration of unsaturated PC species
(PC16:0/18:1 and PC18:0/18:2). However, despite these
apparent improvements to surfactant composition, theFigure 5 Comparison of total bronchoalveolar lavage surfactant phos
PC16:0/14:0 (C), PC16:0/16:1 (D), PC16:0/18:2 (E) and PC16:0/18:1 (F) e
†, P < 0.05. PC, phosphatidylcholine.fractional content of unsaturated PC species remained
significantly elevated at 96 hours, with PC16:0/16:0 being
still low at 40.6 ± 7.0%. The sum of surfactant specific PC
species (PC16:0/16:0, PC16:0/14:0 and PC16:0/16:1) was
consistently between 70-75% for healthy controls, but
was widely variable for patients at enrolment (14- 59%,
Figure 4).phatidylcholine (A) and fractional methyl-D9 PC16:0/16:0 (B),
nrichment in patients and controls. Data presented as mean ± SEM,
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methyl- D9-choline enrichment
Despite the lower concentration of BALF PC in ARDS
patients compared to controls (Figure 2), the fractional
enrichments of methyl-D9-choline into both total PC
and PC16:0/16:0 were consistently higher in patients
compared with healthy controls (Figure 5). Expressed as
a percentage of total labelled plus endogenous PC, the
fractional enrichment of methyl-D9-choline into total PC
for patients increased from 0.19 ± 0.05% at 6 hours to a
maximum value of 0.90 ± 0.2% at 48 hours and then
remained constant until 96 hours. Compared to controls,
this represented 77% and 73% increases in total PC enrich-
ment at 24 and 48 hours respectively (Figure 5A).
The fractional PC16:0/16:0 methyl-D9 enrichment for
patients reflected that of total PC, but with a time delay.
PC16:0/16:0 methyl-D9 enrichment at 6 hours (0.09 ±
0.03%) was much lower than total PC enrichment for
this time point and maximal enrichment was not observed
until 72 hours (0.79 ± 0.08%) (Figure 5B). Although,Figure 6 Bronchoalveolar lavage surfactant total phosphatidylcholine
patients and controls. A, Individual variation in the total PC methyl-D9 en
methyl-D9 enrichment among patients; C, Individual variation in the total P
PC16:0/16:0 methyl-D9 enrichment among controls.compared to healthy controls methyl-D9-PC16:0/16:0
enrichments were higher in patients, statistical significance
(P < 0.05) was only noted at 48 hours after methyl-D9
choline infusion. Other major PC species also showed sig-
nificant increases in the fractional methyl-D9 enrichment
compared to healthy controls (Figure 5C, D, E, and F).
However, these mean enrichment values masked wide
variations for individual patients in both magnitude of
label enrichment and the time required to achieve max-
imal enrichment for both total methyl-D9-PC (Figure 6A)
and methyl-D9-PC16:0/16:0 (Figure 6B). For instance,
the time of maximal enrichments for both parameters
varied from 24 to 72 hours for individual patients. While
the corresponding enrichments for controls at both 24
and 48 hours exhibited a similar variation to patients
(Figure 6C and 6D), we were unable to determine their
variation in time to maximal enrichment. Unfortunately,
without measurement of the isotopic enrichment of the
methyl-D9 label in the phosphocholine substrate pool
within AT- II cells, no calculation of a fractional syntheticand fractional PC16:0/16:0 enrichment patterns for individual
richment among patients; B, Individual variation in the PC16:0/16:0
C methyl-D9 enrichment among controls; D, Individual variation in the
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for individual variation in substrate isotopic enrichment.
An alternative approach to calculate FSR from the initial
gradient of isotopic enrichment divided by the plateau value
displayed a three-fold variation for the 9 patients who sur-
vived beyond 24 h, but values for those patients who died
was not significantly different from those who survived
(Figure 7). Over the 96 hours duration of this study, there
was no substantial decrease in methyl-D9 choline enrich-
ment into BALF PC in the patient group, precluding
any calculation of fractional catabolic rate (FCR).
Molecular composition of newly synthesised PC species
The molecular composition of newly synthesised and
secreted PC species in BALF from patients, quantified
from precursor scans of P193 (Figure 1), varied consider-
ably with time after methyl-D9-choline infusion (Figure 8A).
PC synthesis composition at the earliest time point (T = 06
Hrs) after methyl-D9 choline infusion was dominated by
the unsaturated species PC16:0/18:1 (22.5 ± 3.6%) and
PC16:0/18:2 (13.1 ± 1.8%). The fractional labelling of
PC16:0/16:0 gradually increased from 11 ± 1.9% at 6 hours
to 25.4 ± 2.7%, 32 ± 2.2%, 35.2 ± 3.6% and 33.6 ± 3.9% of
total labelled PC at 24, 48, 72 and 96 hours respectively,
accompanied by a corresponding decreased fractional
labelling of unsaturated PC species, particularly PC16:0/
18:1 from 22.5 ± 3.6% at 6 h to 14.2 ± 4.1% at 96 hours
after choline infusion (Figure 8A).
In patients, the gradual increase of fractional labelled
PC16:0/16:0 lagged behind the improvement of endogen-Figure 7 Fractional synthetic rate (FSR) of phosphatidylcholine
enrichment in BALF samples from patients with ARDS. Results
were calculated as the initial gradient of enrichment divided by the
plateau enrichment expressed as a percentage. While there was a
three-fold range in values, there was no significant difference for
those who survived (mean = 1.64 h−1) and those patients who
died (mean = 1.40 h−1, P = 0.36).ous PC16:0/16:0 composition with time. At the earliest
time point (T = 06 Hrs) after methyl-D9 choline infusion,
the newly synthesised fraction of PC16:0/16:0 was signifi-
cantly lower than that of the endogenous fraction (newly
synthesised 11 ± 1.9% versus endogenous 25.2 ± 2.9%), but
achieved near equilibrium by 48 hours (Figure 8B). For
healthy controls, methyl-D9 enrichment into BALF PC
was only determined at 24 and 48 hours. Comparing
patients and controls at 24 hours, while fractional labelling
of PC16:0/16:0 in healthy controls was lower than en-
dogenous composition (48.4 ± 1.2% vs 56.1 ± 0.9%), this
difference was significantly greater for the patient group
(25.4 ± 2.7 vs 35.8 ± 4.1%). However, similar to patients,
the methyl-D9 labelled PC16:0/16:0 achieved near equilib-
rium with endogenous composition of PC16:0/16:0 at
48 hours in the control group (Figure 8B). In contrast to
the small variation in the percentage composition of newly
synthesised PC16:0/16:0 for the healthy controls, this
value varied considerably for the patients, ranging from
15-47% of total methyl-D9-labelled PC (Figure 8C and
8D). However, with the exception of three patients (P02,
P04 and P08), who had continued lower fractional com-
position of methyl-D9-labelled PC16:0/16:0, this variation
in patients reflected the variation of endogenous fractional
composition of PC16:0/16:0 at 48 hours (at overall peak
PC methyl-D9-enrichment).
Discussion
This study conducted on a small number of ARDS patients
illustrates the feasibility of performing stable isotope label-
ling in combination with ESI-MS/MS analytical methods to
investigate surfactant phospholipid metabolism in a defined
human patient cohort. This is the first study to characterise
the molecular specificity of surfactant synthesis in adult
ARDS population. The study group composed of patients
with moderate to severe ARDS as defined by the degree of
hypoxemia. Most patients (90%) had pneumonia as the
single precipitating factor.
Despite the significant variability, ARDS patients had
persistently lower BALF total PC concentrations compared
to healthy controls. The BALF fractional PC16:0/16:0 abso-
lute concentrations were also much lower in patients and
only accounted for about 10% of the healthy controls. The
decreased fractional PC16:0/16:0 content in our patient
group is comparable with a previous study of patients with
ARDS, where the disaturated PC content of from patients
was only 17% of that of controls [11]. Apparent differences
with other previous reports in ARDS are largely due to
a combination of less severe disease [5] and alternative
methodologies and analysis of purifying isolated surfactant
fractions [2,5,12]. This deficit in total PC and fractional
PC16:0/16:0 concentration may be due to reduced syn-
thesis, increased breakdown, or dilution by pulmonary
oedema. Reduced synthesis in turn could be due to either
Figure 8 Molecular specificity of newly synthesised major bronchoalveolar lavage surfactant phosphatidylcholine fraction in ARDS patients
over time (A), endogenous andmethyl-D9 labelled fractional composition of PC16:0/16:0 for both controls and patients (B), endogenous and
methyl-D9 labelled fractional composition of PC16:0/16:0 for individual controls (C) and patients (D) at 48 hours aftermethyl-D9-choline
infusion. At the earliest time point (T = 06 Hrs) after methyl-D9 choline infusion, unsaturated PC species predominate with subsequent gradual increase
in PC16:0/16:0 over time. PC16:0/16:0 synthesis, expressed as a percentage of newly-synthesised total PC, was compared with that of endogenous PC16:0/
16:0 at two time points for controls and six time points for patients. The proportion of methyl-D9-labelled PC16:0/16:0 was significantly lower than that of
unlabelled PC16:0/16:0, when both are expressed relative to total labelled and unlabelled PC pools, and at 24 hours this deficit is greater in ARDS compared
with control subjects. For both patients and controls, the newly synthesised fraction of PC16:0/16:0 was in equilibrium with endogenous composition at
48 hours after methyl-D9 choline infusion. Presented as mean ± SEM; † P < 0.05. There is considerable variation in the relative proportion of fractional
labelling of PC16:0/16:0 in patients compared to the controls in addition to lower fractional synthesis of PC16:0/16:0 in 3 patients (P02, P04 and P08)
compared with endogenous fraction. Controls (n) =9 and patients (n) =9. PC, phosphatidylcholine. C, individual controls; P, individual patients.
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and secretory mechanisms. However, this was coupled
with increased methyl-D9 choline enrichments of both
total PC and PC16:0/16:0 (Figure 5A and 5B). One pos-
sible explanation for this finding is that the rate of
surfactant PC synthesis in remaining uninjured AT-II
cells must be preserved or even enhanced, but that total
surfactant PC production is indeed decreased probably
due to decreased numbers of functional AT-II cells. This
conclusion support and extend a previous study that
employed in-vivo stable isotope labelling with deuterated
water (2H20) to characterise patterns of enrichment of
newly-synthesised fatty acids into disaturated PC in ARDS
patients [11]. This study also demonstrated increased frac-
tional labelling of disaturated PC, coupled with decreased
concentration, but provided no specific molecular species
analysis. In this context, the interaction between rates of
PC synthesis on the endoplasmic reticulum, its packaging
into lamellar bodies and subsequent secretion will be
critical. One realistic scenario, for instance, could bethat decreased surfactant secretion from a depleted num-
ber of AT-II cells results in accumulation of labelled PC
in existing AT-II cells, which could explain the conun-
drum of decreased concentration, but increased fractional
enrichment of surfactant PC in ARDS patients.
As fractional catabolic rates could not be calculated
for either ARDS patients or healthy controls, no conclu-
sion can be inferred about the potential contribution of
increased surfactant catabolism to decreased BALF PC
concentration in ARDS patients. However, any substantial
increased surfactant catabolism would have been expected
to cause a more rapid decline in PC enrichment in ARDS
patients compared with control subjects. While such a
comparison was not possible in the present study, the dur-
ation of labelling of sputum PC in previous studies [8,13]
was very similar to the enrichment profiles of BALF PC in
ARDS patients shown in Figure 5. Consequently, the most
likely cause of the lower BALF PC concentration in ARDS
patients was a significantly decreased rate of total alveolar
surfactant synthesis.
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patients also revealed abnormal PC composition, with
diminished levels of PC16:0/16:0 and increased fractional
compositions of unsaturated PC species, when compared
to the endogenous composition. We have previously dem-
onstrated in healthy volunteers that, during earlier time
points following methyl-D9-choline infusion, the newly
synthesised surfactant PC complex is different to that of
endogenous composition [8,13]. Furthermore, it takes up
to 48 hours for the labelled methyl-D9-PC16:0/16:0 to
achieve equilibrium with unlabelled PC16:0/16:0 percent-
age composition. If the acyl- remodelling mechanisms
described previously [8,9,13] are complete before sur-
factant secretion, the labelled PC16:0/16:0 composition
should be at equilibrium with endogenous composition
at all-time points. As our data shows this not be the
case, our results are compatible with the previous
healthy volunteer study conclusion, that not all alveolar
surfactant is acyl- remodelled prior to secretion [8,13].
Despite similarities, ARDS patients had much lower
fractional composition of labelled PC16:0/16:0 at all-
time points compared to healthy controls. In-addition,
three patients had comparatively much lower fractional
labelling compared to the endogenous fraction of PC16:0/
16:0 at 48 hours. These findings indicate, that despite an
increase in fractional synthesis, the surfactant PC produced
has abnormal composition with some patients showing
altered acyl-remodelling mechanisms of PC16:0/16:0.
Previous surfactant related clinical studies used gas
chromatographic separation methods to quantify palmitic
acid (16:0) and used the latter as a surrogate for PC16:0/
16:0 [2,5]. This methodology always produced higher
fractional compositional values (70-80%) for palmitic acid
(16:0), which may have come from PC species other than
PC16:0/16:0, and have no clinical relevance. In contrast,
stable isotope labelling of surfactant precursors in com-
bination of ESI-MS/MS analytical approach, is a novel
technique to study dynamic phospholipid flux with precise
molecular analysis. This facilitated for the first time the
assessment of surfactant PC molecular synthesis via CDP-
choline pathway in adult ARDS population.
This is the first study to use small volume BALF to
investigate surfactant metabolism in patients with ARDS.
In the past, investigators have used quantitative BALF to
investigate compositional analysis in ARDS. Although in
general this is a safe procedure, repetitive large volume
BALF may theoretically deplete alveolar surfactant and
may produce a negative clinical impact. Moreover, anec-
dotally desaturations are much more common during
quantitative BALF. The surfactant PC composition in
our control group is similar to previous publications,
which has used large volume BALF for molecular analysis
[12,14]. This suggests, at least in physiological conditions
small volume BALF is comparable to quantitative BALFfor the study of surfactant phospholipid composition and
metabolism. Small volume BALF was tolerated by all,
without any significant immediate complications. Despite
no cardiovascular or respiratory compromise, all patients
needed additional sedation, on average of 40 mgs of pro-
pofol or 2 mgs of midazolam to perform this procedure.
As this was a pilot study with small number of patients,
no clinical correlations or outcome inferences were made.
The study was further limited by the lack of ventilated
control patients, who are more representative as a com-
parable population, than healthy adults. Despite these
limitations, the demonstration of the existence of variable
surfactant composition, synthesis and metabolism among
patients indicate, the presence of underlying phenotypes of
surfactant metabolism. Future similar studies if adequately
powered, may help to explore clinical correlations.
Conclusions
This preliminary data suggest the feasibility of using isotope
labelling technique to study surfactant kinetics in patients
with ARDS. The compositional assessments indicate vari-
ability in the surfactant PC composition, fractional synthesis
and enrichment of newly synthesised surfactant PC species
among patients. This individual variability may pave the
way for phenotypic characterisation of patients according
to surfactant metabolism and subsequent therapeutic
targets.
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